An expert's opinion: Interview with Prof. Christian Giske on the fight against antimicrobial resistance

on November 18, 2026

Professor Christian Giske is a Norwegian microbiologist, Professor of Clinical Bacteriology at the Karolinska Institutet in Sweden, and Head of Antimicrobial Resistance and Healthcare-Associated Infections at the European Centre for Disease Prevention and Control (ECDC). He has spent his career mapping out the molecular secrets of drug-resistant pathogens and engineering the defenses to stop them in their tracks.


Which are the primary epidemiological trends related to antimicrobial resistance (AMR) that are currently being monitored in the EU?

Christian Giske profileChristian Giske: In the section of ECDC that I work at, we are focusing both on AMR and healthcare-associated infections (HAIs), which sometimes overlap. For instance, we know that more than 70% of the health burden of AMR is due to HAIs with multidrug-resistant bacteria.

Regarding AMR specifically, we see that it continues to rise across the European Union and the European Economic Area: this is consistent with the most recent, currently unpublished, data. In fact, we continuously monitor surveillance data on AMR and antimicrobial consumption in Member States. Unfortunately, for some of the pathogens under surveillance there are concerns with increasing resistance.


ECDC's work informs public health actions across EU Member States. What are its major courses of action to address AMR?

Christian Giske: Surveillance data is something that we have been providing for a long time, and it can be used by Member States to evaluate and inform their situation. More recently, we started conducting preparedness assessments in addition to our country visits [the ECDC carries out visits and meetings after an official invitation by Member States, to discuss issues in the country and to provide an evidence-based assessment of the situation].

We also offer genomic surveillance of resistant pathogens, a tool that can be used to track and thereby curb cross-border transmission of AMR pathogens. By using our analysis and observations, we are looking to provide more tailored recommendations to address AMR challenges in different countries.


The EU has established five critical goals to reduce AMR, set to be reached by 2030. Based on the available data, how close are we to achieving those goals?

Christian Giske: Amongst those five targets, one of them is related to the overall consumption of antimicrobials, which should be reduced by 20% as compared to the baseline of 2019. There have been some years with increasing antimicrobial consumption, but we are hoping to turn the trend.

Another target is that 65% of the consumed antimicrobials should be the so-called “access antimicrobials”, meaning the ones with the narrowest spectrum. We are still working towards this goal as well.

The last three targets, all related to resistant pathogens, bring some good and bad news. One of them aims to reduce the incidence of bloodstream infections caused by meticillin-resistant Staphylococcus aureus, a particularly problematic strain of S. aureus, one of the most common blood culture pathogens. This goal is going in the right direction: there are some annual shifts, so it is too difficult to be certain, but it looks good.

On the other hand, a problematic aspect is that we are observing an increase in bloodstream infections caused by third-generation cephalosporin-resistant Escherichia coli, and an even sharper increase in carbapenem-resistant Klebsiella pneumoniae. Genomic investigations show that this can be explained by some major strain spreading in hospitals, particularly in some areas. Surely, this is part of a concerning picture.


How are you working to bridge the gap between the current situation and the 2030 goals?

Christian Giske: There are two main ways of helping the countries improve the situation. One of them is to empower them in improved infection prevention and control practices. Our role in this case is to provide information, guidelines and practical tools to facilitate this process in Member States.

The other way pertains to the antimicrobial consumption patterns: we need to start considering not only traditional measures, but also social and behavioural changes, that can create awareness in the community, bringing attention to this important discussion.


Each year on 18 November, ECDC promotes the European Antibiotic Awareness Day (EAAD). What are the most important messages you wish to convey through this initiative this year?

Christian Giske: This year, we are focusing on children - particularly infants and preschool-aged children, because they are heavily exposed to antibiotics, often without need: many common childhood infections do not require antibiotics. That is why, if we were able to reduce antibiotic use in this group of patients, it could be a big factor in the overall discussion about how to reduce consumption.

Apart from that, we would like to again show that facing AMR is really a joint responsibility, no single level can be entirely responsible. Policy makers, governmental and non-governmental organisations, practitioners, parents, and patients all have a role to play.


Thinking about advisory and policy work, what are the milestones that your team at ECDC is looking forward to?

Christian Giske: We are now working with an One Health approach with all the EU Member States, and this means we have an extensive interagency collaboration.

For example, we published four Joint Interagency Antimicrobial Consumption and Resistance Analysis (JIACRA) reports, which are interagency reports produced by the European Food Safety Authority, the European Medicines Agency, and the ECDC to establish connectivity between different One Health sectors, such as human medicine and food-producing animals.

Finding this connectivity between different sectors is not always easy, but particularly in terms of some foodborne pathogens such as Campylobacter, we can clearly see that there are connections related to antimicrobial consumption in food-producing animals and how resistant bacteria can subsequently spread to people through food.

In the future, there will be a stronger focus on integrating environmental aspects as well, extending the collaboration to the European Environment Agency and improving cooperation with other agencies, like the European Chemicals Agency. Importantly, the ECDC has also started an initiative to manage AMR and strengthen One Health in Africa, where the European Food Safety Authority is also involved, together with the Africa Centres for Disease Control and Prevention.

Related article